So far this year, Eli Lilly (NYSE: LLY) has been on an absolute tear and is swiftly becoming the world's most prolific ...

On this episode of Fortune’s Leadership Next podcast, host Diane Brady talks to Eli Lilly chair ... with the scientific team ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Management also lowered the midpoint ... The Motley Fool Stock Advisor analyst team just identified what they believe are the ...

Almost all cases of ALS and half of frontotemporal dementia (FTD) cases are linked to dysfunction in a protein TDP-43.

Despite the above, there are still a couple of silver linings that provide more than enough reason to be bullish about this stock.

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), the kings of the titanic weight-loss drugs market, might have a problem on their hands. After reporting their third-quarter earnings, shares of both ...

INDIANAPOLIS (AP) — Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two key drugs that missed expectations. The drugmaker ...

Ladies and gentlemen, thank you for standing-by, and welcome to the Lilly Q3 2024 Earnings Call. [Operator Instructions] I ...

Pfizer has a well-diversified pipeline, with several late-stage assets to drive medium-term growth. Learn more about PFE ...

In addition to top-line figures that missed Wall Street expectations, management ... team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn ...